

8.30-9.15 a.m. Registration

9.15-9.30 a.m. Welcome

9.30-10.45 a.m. Lectures : Session 1 – Miscellaneous

9.30-9.55 a.m. Prefrontal dopamine and cognitive impairment in schizophrenia
(Elsmarieke Van de Giessen Amsterdam, The Netherlands)

9.55-10.20 a.m. SEEG validation of 18FDG-PET in different subtypes of temporal lobe epilepsy
(Eric Guedj, Marseille, France)

10.20-10.45 a.m. Brain connectivity beyond structure and function to understand age-related
cognitive disorders (Gael Chetelat, Caen, France)

10.45-11.15 a.m. Coffee Break and poster session

11.15-12.35 p.m. Oral communications (Session 1)

12.35-1.35 p.m. Lunch Break and poster session

1.35-2.50 p.m. Lectures : Session 2 – Modeling/Quantification

1.35-2.00 p.m. Approaches to semi-quantification: beyond SUVr in amyloid imaging (Andrea
Chincarini, Genoa, Italy)

2.00-2.25 p.m. Therapy Assessment: Quantification vs Simplification (Adrian Lammertsma,
Amsterdam, The Netherlands)

2.25-2.50 p.m. AD subtypes (FDG): linear mixed effects models of regional values (Karl Herholz,
Manchester, England)

2.50-3.35 p.m. Special lecture (Industry)

2.50-3.35 p.m. TBD

3.35-4.05 p.m. Coffee Break and poster session

4.05-4.55 p.m. Lectures : Session 3 – Movement Disorders

4.05-4.30 p.m. PET/SPECT imaging of cognitive impairment in Parkinson's disease (Sabina
Pappatà, Naples, Italy)

4.30-4.55 p.m. PET and SPECT imaging in movement disorders: new developments (Jan Booij,
Amsterdam, The Netherlands)

4.55-6.05 p.m. Oral communications (Session 2)

8.00-8.45 a.m. Registration

8.45-10.00 a.m. Lectures : Session 4 – PET-MRI

8.45-9.10 a.m. Performance and Workflow with current PET/MRI-Systems (Bernhard Sattler, Leipzig, Germany)

9.10-9.35 a.m. Neuro-pediatric PET/MRI (Ian Law, Copenhagen, Denmark)

9.35-10.00 a.m. Clinical impact of PET and MRI in parkinsonism (Valentina Berti, Florence, Italy)

10.00-10.25 a.m. Clinical use of PET-MRI imaging in dementias (Valentina Garibotto, Geneva, Switzerland)

10.25-10.55 a.m Coffee Break and poster session

10.55-12.10 p.m. Lectures : Session 5 - Dementia

10.55-11.20 a.m. Investigation of Alzheimer's disease: FDG-PET, ME-MRI, to cytoskeletal stabilizing therapy (Satoshi Minoshima, Salt Lake City, USA)

11.20-11.45 a.m. MRI and EEG biomarkers along disease progression in amnesic MCI subjects with prodromic AD in European ADNI (Claudio Babiloni, Rome, Italy)

11.45-12.10 p.m. Update and new developments in tau imaging (Victor Villemagne, Austin, Australia)

12.10-12.40 p.m. Special lecture (Industry)

12.10-12.40 p.m. TBD

12.40-1.40 p.m. Lunch Break and poster session

1.40-2.20 p.m. Oral communications (Session 3)

2.20-3.35 p.m. Lectures : Session 6 – Onco-PET

2.20-2.45 p.m. On the horizon: Ultra-High-Field Imaging in Neurooncology (Alexander Radbruch, Heidelberg, Germany)

2.45-3.10 p.m. Clinical impact of 18F-FDOPA PET in the diagnosis of recurrent brain tumors (Jacques Darcourt, Nice, France)

3.10-4.10 p.m. Oral communications (Session 4)

4.10-4.30 p.m. Discussion and conclusions